Change over period: —
NSE · BALAXI
Balaxi Pharmaceuticals Ltd
-18.8% from the 52-week high · +102.0% above the low
Balaxi Pharmaceuticals Ltd. engages in the exportation of pharmaceutical, hardware, and FMCG products. The company is headquartered in Hyderabad, Telangana and currently employs 51 full-time employees. The company went IPO on 2015-11-30. The firm is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. The company has a portfolio across multiple therapeutic segments, stock & sell models, and supplying branded and generic medicines. The firm is offerings more than 300 products across multiple therapeutic areas, including Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhoea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents and Laxative. Its consumer products include Nice 45 G, Guloso 45 G, Snax! 42 G, Doce E Sal 42 G, Yumm 75 G and Boadent.
The short version. Balaxi Pharmaceuticals Ltd reported revenue of ₹81 crore for Sep 2026, up 44.6% from a year earlier. Return on equity was 0.6% in Mar 2026. Promoter holding was 65.99% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
Balaxi Pharmaceuticals Ltd trades 18.8% below its 52-week high and 102.0% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹81 cr.
1.0 pts higher than a year earlier.
Revenue compounded at -7.0% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 81 | 81 | 71 | 73 | 56 | 71 | 76 | 73 |
| Net profit | 1 | 1 | 1 | 0 | 0 | 0 | 9 | 5 |
| Net margin % | 1.4 | 1.6 | 0.9 | 0.4 | 0.4 | 0.4 | 11.3 | 7.3 |
| EPS (₹) | 0.21 | 0.24 | 0.11 | 0.06 | 0.04 | 0.05 | 1.56 | 0.97 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|
| Revenue | 270 | 293 | 241 | 336 | 279 | 231 | 46 |
| Net profit | 1 | 25 | -2 | 46 | 48 | 37 | 6 |
| Net margin % | 0.5 | 8.6 | -1.0 | 13.7 | 17.1 | 16.1 | 13.4 |
| EPS (₹) | 0.26 | 4.54 | -0.44 | 9.03 | 9.53 | 7.45 | 1.22 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 0.6% in Mar 2026; debt to equity is 0.22.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 0.6 | 10.8 | -1.2 | 25.1 |
| Return on capital % | 3.4 | 12.3 | 1.8 | 30.8 |
| EBITDA margin % | 4.2 | 11.6 | 2.4 | 17.4 |
| Net margin % | 0.5 | 8.7 | -1.0 | 13.6 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | -7.0% | 3.2% |
| Profit CAGR | -68.6% | -48.0% |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Up 2.54 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 65.99 | 65.99 | 65.99 | 65.99 | 65.99 | 65.99 | 65.99 | 65.99 | 0.0 |
| FII | 16.48 | 16.02 | 8.87 | 3.5 | 1.74 | 0 | 0 | 0 | -16.48 |
| DII | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 2.56 | 2.56 | 2.56 | +2.54 |
| Public | 17.5 | 17.96 | 25.12 | 30.49 | 32.24 | 31.45 | 31.45 | 31.45 | +13.95 |
Mutual fund holdings · Oct 2026
0 schemes hold this stock
0 the month before.
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for Balaxi Pharmaceuticals Ltd are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about Balaxi Pharmaceuticals Ltd
What is the Balaxi Pharmaceuticals Ltd share price?
Balaxi Pharmaceuticals Ltd (BALAXI) last closed at ₹37.30, up 17.85% on the day. Its 52-week range is ₹15.67 to ₹38.97.
What is the market cap of Balaxi Pharmaceuticals Ltd?
Balaxi Pharmaceuticals Ltd has a market capitalisation of about ₹175 crore. Its price-to-earnings ratio is 52.2.
How are Balaxi Pharmaceuticals Ltd's latest results?
Balaxi Pharmaceuticals Ltd reported revenue of ₹81 crore for Sep 2026, up 44.6% from a year earlier. Return on equity was 0.6% in Mar 2026. Promoter holding was 65.99% in Sep 2026, up 0.00 points over 8 quarters.
Who owns Balaxi Pharmaceuticals Ltd?
As of Sep 2026, shareholding was: Promoter 65.99%, DII 2.56%, Public 31.45%.
How many mutual funds hold Balaxi Pharmaceuticals Ltd?
0 mutual fund schemes held Balaxi Pharmaceuticals Ltd in October 2026. That compares with 0 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 30 May 2024 · Stock Split From Rs.10/- to Rs.2/-
- 01 Jul 2022 · Dividend - Rs. 0.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.